Navigation Links
RiboMed Receives Three Additional Patents for Disease Diagnostics Methods

CARLSBAD, CA (PRWEB) December 05, 2012

“These patent issuances further solidify RiboMed’s position in clinical diagnostics, particularly in the use of DNA Methylation biomarkers for cancer detection, staging and drug development” stated Dr. Michelle Hanna, Chief Executive Officer and Scientific Director of RiboMed. “The technologies protected by these patents make sensitive, reproducible and quantitative DNA methylation profiling possible even on formalin fixed paraffin embedded (FFPE) tumor tissues, as we have shown with the G-CIMP DecisionDx test launched in RiboMed’s CLIA laboratory earlier this year.” G-CIMP stands for Glioma specific CpG Island Methylator Phenotype, and the test predicts the aggressiveness of certain brain tumors, providing physicians and patients with a new tool for making treatment decisions. The test was developed in partnership with Castle Biosciences.

The claims of U.S. Patent 8,263,339, entitled “Abscription based molecular detection” broadly cover RiboMed’s core Abscription technology for use in detecting a wide variety of molecular biomarkers, including DNA, RNA, protein and methylated DNA. Detection tests reduced to practice in addition to those for DNA methylation include sensitive and robust assays for Salmonella (DNA), viral RNAs and protein toxins, such as ricin, Botulinum toxin and the food poisoning agent, SEB. These assays were developed together with the Departments of Defense (DARPA) and Homeland Security (HSARPA).

U.S. Patent 8,242,243, entitled “Methods and reagents for detecting CpG methylation with a methyl CpG binding protein (MBP)” covers a highly quantitative and sensitive, bisulfite-free method for measuring DNA methylation at CpG sites and CpG islands using RiboMed’s proprietary Methyl CpG binding fusion protein. This work was supported in part by Small Business Innovative Research grant and contract awards from the National Cancer Institute. In addition to the currently available brain cancer staging test, RiboMed is developing similar DNA methylation profile based diagnostic, prognostic and companion diagnostic tests for ovarian and lung cancers.

Finally, U.S. Patent 8,211,644, entitled “Molecular beacon based methods for detection of targets using Abscription” provides claims to sensitive fluorescence-based methods using molecular beacons to detect the products of Abscription and makes real time detection methods possible. The molecular beacon-based technology makes Abscription more attractive to the vast majority of clinical and research laboratories that do not have access to a mass spectrometer, which is used for the current G-CIMP assay, but routinely use fluorescence detection instruments. The molecular beacon format allows for more streamlined workflows and faster assay set-up. The new fluorescence read-out is readily adapted for the detection of RNA, DNA and protein targets and should have wide applicability in areas such as cancer diagnostics and environmental testing.

About RiboMed Biotechnologies, Inc.
RiboMed Biotechnologies, Inc. ( is a molecular diagnostic company providing proprietary epigenetic and genetic biomarker tests for applications in Personalized Medicine and Companion Diagnostics, which is the use of information about an individual’s cellular biomarkers to detect and treat disease. The current focus of the Company is on the detection of epigenetic biomarkers (DNA methylation) and genetic biomarkers associated with disease initiation, progression and response to drug treatment.

RiboMed provides products and services for disease management and drug development utilizing its proprietary and patented technologies for biomarker detection (Abscription®) and methylated DNA isolation and quantification (MethylMagnet® and MethylMeter®). In February, 2011, the Company expanded to add the RiboMed Clinical Services Laboratory (RCSL, CLIA License #05D2020043).

For more information, contact:
    Michelle Hanna, Ph.D.
    CEO & Scientific Director

This press release contains forward-looking statements and estimates with respect to the anticipated future performance of RiboMed and the market in which it operates. Such statements and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable but may not prove to be correct. Actual events are difficult to predict, may depend upon factors that are beyond the Company’s control, and may turn out to be materially different. RiboMed expressly disclaims any obligation to update any such forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based unless required by law or regulation.

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. BioNeutral Group Receives Positive Testing Results From A Global Independent Laboratory For Its Ygiene Sterilant Against Anthrax Spores
2. iBio, Inc. Receives Notice from NYSE MKT Staff that Company Currently is Below Certain Continued Listing Standards
3. AtheroNova Receives Notice of Issuance of Its U.S. Patent 8,304,383
4. Ceres Receives $3.5 million from USAID for Trait Stacks
5. Creabilis Receives Prestigious Technology Strategy Board Biomedical Catalyst Award
6. Hertz Fellow, Grant I. Gillary, Receives Hertz Foundation-George Lerman Fellowship
7. Sinovac Biotech Receives GMP Certification for Mumps Vaccine Production Facility
8. Lifeline Biotechnologies Receives Patent for Methods to Collect and Analyze Breast Thermal Data to Determine Suspect Conditions
9. Northwest Bio Receives Regulatory Approval To Proceed With Its Phase III Trial In The UK
10. Rosetta Genomics Receives 2012 North American Entrepreneurial Company of the Year Award by Frost & Sullivan
11. Perrigo Receives FDA Approval And Commences Launch Of Morphine Sulfate 100ml/5% Oral Solution
Post Your Comments:
(Date:6/27/2016)... -- Liquid Biotech USA , Inc. ... Research Agreement with The University of Pennsylvania ("PENN") ... patients.  The funding will be used to assess ... outcomes in cancer patients undergoing a variety of ... to support the design of a therapeutic, decision-making ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Researchers at ... most commonly-identified miRNAs in people with peritoneal or pleural mesothelioma. Their findings are the ... read it now. , Diagnostic biomarkers are signposts in the blood, lung fluid ...
(Date:6/23/2016)... SILVER SPRING, Md. , June 23, 2016 ... evidence collected from the crime scene to track the criminal ... sick, and the U.S. Food and Drug Administration (FDA) uses ... Sound far-fetched? It,s not. ... whole genome sequencing to support investigations of foodborne illnesses. Put ...
(Date:6/23/2016)... , June 23, 2016   EpiBiome , ... secured $1 million in debt financing from Silicon Valley ... up automation and to advance its drug development efforts, ... new facility. "SVB has been an incredible ... the services a traditional bank would provide," said Dr. ...
Breaking Biology Technology:
(Date:6/16/2016)... 16, 2016 The global ... to reach USD 1.83 billion by 2024, according ... Inc. Technological proliferation and increasing demand in commercial ... to drive the market growth.      ... The development of advanced multimodal techniques for biometric ...
(Date:6/9/2016)...  Perkotek an innovation leader in attendance control systems is proud to announce the ... employers to make sure the right employees are actually signing in, and to even ... ... ... ...
(Date:6/7/2016)... , June 7, 2016  Syngrafii Inc. ... a business relationship that includes integrating Syngrafii,s patented ... branch project. This collaboration will result in greater ... the credit union, while maintaining existing document workflow ... ...
Breaking Biology News(10 mins):